Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial

Torquil Watt, Per Cramon, Jakob Bue Bjorner, Steen Joop Bonnema, Ulla Feldt-Rasmussen, Christian Gluud, Jeppe Gram, Jane Lindschou Hansen, Laszlo Hegedüs, Nils Knudsen, Pernille Bach-Mortensen, Runa Nolsøe, Birte Nygaard, Flemming Pociot, Maria Skoog, Per Winkel, Ase Krogh Rasmussen, Torquil Watt, Per Cramon, Jakob Bue Bjorner, Steen Joop Bonnema, Ulla Feldt-Rasmussen, Christian Gluud, Jeppe Gram, Jane Lindschou Hansen, Laszlo Hegedüs, Nils Knudsen, Pernille Bach-Mortensen, Runa Nolsøe, Birte Nygaard, Flemming Pociot, Maria Skoog, Per Winkel, Ase Krogh Rasmussen

Abstract

Background: Graves' hyperthyroidism is an autoimmune disease causing hyperfunction of the thyroid gland. The concentration of selenium is high in the thyroid gland and two important groups of enzymes within the thyroid are selenoproteins, that is, they depend on selenium. Selenium may have beneficial effects on autoimmune hypothyroidism and on Graves' orbitopathy, but the effects of selenium on Graves' hyperthyroidism is unknown.We hypothesize that adjuvant selenium may be beneficial in the treatment of Graves' hyperthyroidism. The objective is to investigate if selenium supplementation plus standard treatment with anti-thyroid drugs versus standard treatment with anti-thyroid drugs will lead to a decrease in anti-thyroid drug treatment failure (that is, failure to remain euthyroid, without further treatment, one year after cessation of anti-thyroid drug treatment), faster and longer lasting remission (that is, anti-thyroid drug treatment success), and improved quality of life in patients with Graves' hyperthyroidism.

Methods and design: The trial is an investigator-initiated, randomised, blinded, multicentre clinical trial. Inclusion criteria are: age 18 years or older; diagnosis of active Graves' hyperthyroidism within the last two months; and informed consent. Exclusion criteria are major co-morbidity; previous radioactive iodine treatment; ongoing anti-thyroid drug treatment for more than two months; treatment with immunomodulatory drugs; known allergy towards the components in the selenium and placebo pills; pregnancy or breast-feeding; and intake of selenium supplementation above 70 μg per day. We plan to include 492 participants, randomised (1:1) to two tablets of 100 μg selenium once daily for the 24 to 30 months intervention period versus two identical placebo tablets once daily.The primary outcome is the proportion of participants with anti-thyroid drug treatment failure (see above) at the end of the intervention period (24 to 30 months). Secondary outcomes are: thyroid-specific quality of life during the first year after randomisation; level of thyroid stimulating hormone-receptor antibodies at 18 months after randomisation and at the end of the intervention period (24 to 30 months); hyperthyroid symptoms during the first year after randomisation; eye symptoms during the first year after randomisation, and at the end of the intervention period (24 to 30 months); adverse reactions during the intervention period; and serious adverse events during the intervention period.

Discussion: It was of great importance to the initiators of this trial, that the results would be directly applicable to daily clinical practice. Therefore, it was designed as a pragmatic trial: the patients follow their usual treatment at their usual hospitals. In order to still collect high quality data on the clinical course and quality of life, an elaborate trial management system was designed to keep track of patient input, need for trial personnel input and action, and to collect data from medical chart systems. Meticulous follow-up on missing responses to the QoL measurements has been incorporated into the system, to minimise missing quality of life data. Monitoring of adverse reactions and events is achieved by thorough instruction of the participants, surveillance of patient-reported outcomes, and integration with national databases regarding hospitalizations. A very long intervention period was necessary, since patients are not considered in remission until one year after stopping anti-thyroid drugs. Usually, patients are treated for 12 to 18 months with anti-thyroid drugs, yielding a total intervention period of 24 to 30 months.

Trial registration: ClinicalTrials.gov: NCT01611896.

Figures

Figure 1
Figure 1
Trial flow chart.
Figure 2
Figure 2
Duration of the intervention.

References

    1. Cerqueira C, Knudsen N, Ovesen L, Perrild H, Rasmussen LB, Laurberg P, Jorgensen T. Association of iodine fortification with incident use of antithyroid medication–a Danish Nationwide Study. J Clin Endocrinol Metab. 2009;94:2400–2405. doi: 10.1210/jc.2009-0123.
    1. Hegedus L. Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin North Am. 2009;38:355–71. doi: 10.1016/j.ecl.2009.01.009.
    1. Watt T, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedüs L, Bjorner JB, Feldt-Rasmussen U. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol. 2006;154:501–510. doi: 10.1530/eje.1.02124.
    1. Rasmussen LB, Mejborn H, Andersen NL, Dragsted LO, Krogholm KS, Larsen EH. Selen og Sundhed. Copenhagen: Danmarks Fødevareforskning; 2006.
    1. Duntas LH. Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab. 2010;95:5180–5188. doi: 10.1210/jc.2010-0191.
    1. Food and Nutrition Board IoM. Dietary reference intakes for vitamin C, vitamin E, selenium and carotenoids. In: Poillon F, Newberry S, editor. Food and Nutrition Board, I.o.M. Washington, D.C: National Academy Press; 2000. p. 1.
    1. Scientific Committee on Food. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level for Selenium. 1. 2000. Brussels: European Commission. Scientific Committee on Food; 2000.
    1. Marcocci C, Leo M, Altea MA. Oxidative stress in Graves' disease. European Thyroid Journal. 2012;1:80–87. doi: 10.1159/000337976.
    1. Duntas LH. The role of selenium in thyroid autoimmunity and cancer. Thyroid. 2006;16:455–460. doi: 10.1089/thy.2006.16.455.
    1. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von AG, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011;364:1920–1931. doi: 10.1056/NEJMoa1012985.
    1. Vrca VB, Skreb F, Cepelak I, Romic Z, Mayer L. Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta. 2004;341:55–63. doi: 10.1016/j.cccn.2003.10.028.
    1. Vrca VB, Skreb F, Cepelak I, Mayer L. Supplementation with antioxidants in the treatment of Graves' disease: the effect on the extracellular antioxidative parameters. Acta Pharm. 2004;54:79–89.
    1. Wertenbruch T, Willenberg HS, Sagert C, Nguyen TB, Bahlo M, Feldkamp J, Groeger C, Hermsen D, Scherbaum WA, Schott M. Serum selenium levels in patients with remission and relapse of graves' disease. Med Chem. 2007;3:281–284. doi: 10.2174/157340607780620662.
    1. Gartner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002;87:1687–1691. doi: 10.1210/jc.87.4.1687.
    1. Gartner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis. Biofactors. 2003;19:165–170. doi: 10.1002/biof.5520190309.
    1. Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol. 2003;148:389–393. doi: 10.1530/eje.0.1480389.
    1. Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol. 2006;190:151–156. doi: 10.1677/joe.1.06661.
    1. Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. Thyroid. 2007;17:609–612. doi: 10.1089/thy.2007.0040.
    1. Nacamulli D, Mian C, Petricca D, Lazzarotto F, Barollo S, Pozza D, Masiero S, Faggian D, Plebani M, Girelli ME, Mantero F, Betterle C. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf) 2010;73:535–539.
    1. Karanikas G, Schuetz M, Kontur S, Duan H, Kommata S, Schoen R, Antoni A, Kletter K, Dudczak R, Willheim M. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid. 2008;18:7–12. doi: 10.1089/thy.2007.0127.
    1. Pentel P, Fletcher D, Jentzen J. Fatal acute selenium toxicity. J Forensic Sci. 1985;30:556–562.
    1. Högberg J, Alexander J. In: Handbook on the toxicology of metals. Friberg L, Nordberg GF, Vouk VB, editor. Amsterdam: Elsevier; 1986. Selenium; pp. 482–520.
    1. Yang GQ, Wang SZ, Zhou RH, Sun SZ. Endemic selenium intoxication of humans in China. Am J Clin Nutr. 1983;37:872–881.
    1. Longnecker MP, Taylor PR, Levander OA, Howe M, Veillon C, McAdam PA, Patterson KY, Holden JM, Stampfer MJ, Morris JS. Selenium in diet, blood, and toenails in relation to human health in a seleniferous area. Am J Clin Nutr. 1991;53:1288–1294.
    1. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957–1963. doi: 10.1001/jama.1996.03540240035027.
    1. Rayman MP. The use of high-selenium yeast to raise selenium status: how does it measure up? Br J Nutr. 2004;92:557–573. doi: 10.1079/BJN20041251.
    1. International Conference on Harmonisation Guideline for International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Guideline for Good Clinical Practice E6 (R1). ICH Harmonised Tripartite Guideline. 10-6-1996. .
    1. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116–128. doi: 10.1016/0197-2456(90)90005-M.
    1. Lantz M, Abraham-Nordling M, Svensson J, Allin G, Allengren B. Immigration and the incidence of Graves' thyrotoxicosis, thyrotoxic multinodular goiter and solitary toxic adenoma. Eur J Endocrinol. 2009;160:201–206.
    1. Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J. 2008;50:667–677. doi: 10.1002/bimj.200710464.
    1. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Authorship and Contributorship. 2010. .
    1. Ware JH, Hamel MB. Pragmatic trials–guides to better patient care? N Engl J Med. 2011;364:1685–1687. doi: 10.1056/NEJMp1103502.

Source: PubMed

3
Tilaa